HEART2BEAT
Financiado
Advanced human models of the heart to understand cardiovascular disease
Cardiovascular diseases (CVD) are the cause of the highest mortality and morbidity rates worldwide and are expected to increase in coming years, leading to epidemic proportions. Traditional experimental in vitro and animal models...
Cardiovascular diseases (CVD) are the cause of the highest mortality and morbidity rates worldwide and are expected to increase in coming years, leading to epidemic proportions. Traditional experimental in vitro and animal models are not predictive enough, which hampers the emergence of novel therapies for treatment of CVD. Consequently, there is an urgent need to establish realistic human models that lead to a better understanding of CVD, providing the opportunity to identify and validate druggable targets. In Heart2Beat I will develop innovative human heart models for mimicking cardiovascular disease. I will use an innovative in-air microfluidic platform for ultra-high throughput encapsulating of human pluripotent stem cells in microgels to generate self-organised multicellular 3D human cardiac organoids that replicate the architectural design of the human heart. Furthermore, I will integrate and develop innovative technologies from the fields of human stem cell biology and engineering to create 3D (micro)-engineered heart tissues, coupled to a versatile and automated microfluidic platform, enabling assessment of multifunctional analysis (e.g., contraction, relaxation, metabolism, morphology). Finally, I will build a functional human mini-heart with the capacity to pump fluid, the main function of the human heart and then assess clinically relevant readouts in healthy and diseased conditions. These first-of-its kind advanced 3D human cardiac models and platforms are complementary to each other and form a highly innovative and comprehensive pipeline for modelling human CVD, enabling (ultra)high throughput screening and in-depth multifunctional pre-clinical analysis of healthy and diseased heart tissues. Successful implementation of Heart2Beat will provide insight into mechanisms of disease and will initiate a paradigm shift for personalised medicine and drug discovery, leading to tailor-made therapy for patients suffering from CVD.
ver más
Duración del proyecto: 65 meses
Fecha Inicio: 2023-06-12
Fecha Fin: 2028-11-30
Fecha Fin: 2028-11-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-06-12
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2022-ADG:
ERC ADVANCED GRANTS
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
3M€
Líder del proyecto
UNIVERSITEIT TWENTE
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5